

Review

Open Access

## Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options

David M Murdoch\*<sup>1,3,5</sup>, Willem DF Venter<sup>2</sup>, Annelies Van Rie<sup>3</sup> and Charles Feldman<sup>4</sup>

Address: <sup>1</sup>Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham North Carolina, USA, <sup>2</sup>Reproductive Health & HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa, <sup>3</sup>Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, <sup>4</sup>Division of Pulmonology, Department of Medicine, Johannesburg Hospital and University of the Witwatersrand, Johannesburg, South Africa and <sup>5</sup>CB#7435, 2104-H McGavran-Greenberg Hall, University of North Carolina, School of Public Health, Chapel Hill, NC 27599-7435, USA

Email: David M Murdoch\* - [dmurdoch@email.unc.edu](mailto:dmurdoch@email.unc.edu); Willem DF Venter - [f.venter@rhrujhb.co.za](mailto:f.venter@rhrujhb.co.za); Annelies Van Rie - [vanrie@email.unc.edu](mailto:vanrie@email.unc.edu); Charles Feldman - [charles.feldman@wits.ac.za](mailto:charles.feldman@wits.ac.za)

\* Corresponding author

Published: 8 May 2007

Received: 5 March 2007

*AIDS Research and Therapy* 2007, **4**:9 doi:10.1186/1742-6405-4-9

Accepted: 8 May 2007

This article is available from: <http://www.aidsrestherapy.com/content/4/1/9>

© 2007 Murdoch et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

The immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients initiating antiretroviral therapy (ART) results from restored immunity to specific infectious or non-infectious antigens. A paradoxical clinical worsening of a known condition or the appearance of a new condition after initiating therapy characterizes the syndrome. Potential mechanisms for the syndrome include a partial recovery of the immune system or exuberant host immunological responses to antigenic stimuli. The overall incidence of IRIS is unknown, but is dependent on the population studied and its underlying opportunistic infectious burden. The infectious pathogens most frequently implicated in the syndrome are mycobacteria, varicella zoster, herpesviruses, and cytomegalovirus (CMV). No single treatment option exists and depends on the underlying infectious agent and its clinical presentation. Prospective cohort studies addressing the optimal screening and treatment of opportunistic infections in patients eligible for ART are currently being conducted. These studies will provide evidence for the development of treatment guidelines in order to reduce the burden of IRIS. We review the available literature on the pathogenesis and epidemiology of IRIS, and present treatment options for the more common infectious manifestations of this diverse syndrome and for manifestations associated with a high morbidity.

### Introduction

Since its introduction, ART has led to significant declines in AIDS-associated morbidity and mortality [1]. These benefits are, in part, a result of partial recovery of the immune system, manifested by increases in CD4<sup>+</sup>T-lymphocyte counts and decreases in plasma HIV-1 viral loads [2]. After initiation of ART, opportunistic infections (OI)

and other HIV-related events still occur secondary to a delayed recovery of adequate immunity [3].

Some patients initiating ART experience unique symptoms during immune system recovery. In these patients, clinical deterioration occurs despite increased CD4<sup>+</sup>T-lymphocyte counts and decreased plasma HIV-1 viral loads [4]. This clinical deterioration is a result of an

inflammatory response or "dysregulation" of the immune system to both intact subclinical pathogens and residual antigens [5-9]. Resulting clinical manifestations of this syndrome are diverse and depend on the infectious or noninfectious agent involved. These manifestations include mycobacterial-induced lymphadenitis [5], paradoxical tuberculosis reactions [6,7,10,11], worsening of progressive multifocal leukoencephalopathy (PML) [12], recurrence of cryptococcosis and *Pneumocystis jirovecii* pneumonia (PCP) [8,13-16], *Cytomegalovirus* (CMV) retinitis [17], shingles [18], and viral hepatitis [19], as well as noninfectious phenomena [20].

Because clinical deterioration occurs during immune recovery, this phenomenon has been described as immune restoration disease (IRD), immune reconstitution syndrome (IRS), and paradoxical reactions. Given the role of the host inflammatory response in this syndrome, the term immune reconstitution inflammatory syndrome (IRIS) has been proposed [21] and has become the most widely used and accepted term to describe the clinical entity. Possible infectious and noninfectious etiologies of IRIS are summarized in Table 1.

To date, no prospective therapeutic trials concerning the management of IRIS have been conducted. All evidence regarding the management of IRIS in the literature relates to case reports and small case series reporting on management practice. This does not provide reliable evidence regarding either the safety or efficacy of these approaches, but merely guidance regarding the practice of others in managing this difficult condition. In severe cases where the discontinuation of ART is a possibility, the potential disadvantages of therapy cessation, such as the development of viral resistance or AIDS progression, should be considered.

### **Pathogenesis of IRIS**

Despite numerous descriptions of the manifestations of IRIS, its pathogenesis remains largely speculative. Current theories concerning the pathogenesis of the syndrome involve a combination of underlying antigenic burden, the degree of immune restoration following HAART, and host genetic susceptibility. These pathogenic mechanisms may interact and likely depend on the underlying burden of infectious or noninfectious agent.

Whether elicited by an infectious or noninfectious agent, the presence of an antigenic stimulus for development of the syndrome appears necessary. This antigenic stimulus can be intact, "clinically silent" organisms or dead or dying organisms and their residual antigens. IRIS that occurs as a result of "unmasking" of clinically silent infection is characterized by atypical exuberant inflammation and/or an accelerated clinical presentation suggesting a

restoration of antigen-specific immunity. These characteristics differentiate IRIS from incident opportunistic infections that occur on ART as a result of delayed adequate immunity.

Examples of IRIS in response to intact organisms include, but are not limited to, the unmasking of latent cryptococcal infection [22] and infection with *Mycobacterium avium* complex (MAC) [4,5,23,24]. The most frequently reported IRIS symptoms in response to previously treated or partially treated infections include reports of clinical worsening and recurrence of clinical manifestations of *Mycobacterium tuberculosis* (TB) and cryptococcal meningitis following initiation of ART [6,7,10,13,16,25-28]. In noninfectious causes of IRIS, autoimmunity to innate antigens plays a likely role in the syndrome. Examples include exacerbation of rheumatoid arthritis and other autoimmune diseases [29]. Given the role of this antigenic stimulus, the frequency and manifestations of IRIS in a given population may be determined by the prevalence of opportunistic and non-opportunistic infections to initiation of ART.

The mechanism receiving the most attention involves the theory that the syndrome is precipitated by the degree of immune restoration following ART. In assessing this theory, investigators have examined the association between CD4 cell counts and viral loads and the risk of IRIS. Some studies suggest differences in the baseline CD4 profiles or quantitative viral load at ART initiation or their rate of change during HAART between IRIS and non-IRIS patients [4,30-34], while other studies demonstrate only trends or no significant difference between IRIS and non-IRIS patients [7,35]. These immunological differences between groups have been difficult to verify due to small numbers of IRIS cases and lack of control groups. An alternative immunological mechanism may involve qualitative changes in lymphocyte function or lymphocyte phenotypic expression. For instance, following ART an increase in memory CD4 cell types is observed [36] possibly as a result of redistribution from peripheral lymphoid tissue [37]. This CD4 phenotype is primed to recognize previous antigenic stimuli, and thus may be responsible for manifestations of IRIS seen soon after ART initiation. After this redistribution, naïve T cells increase and are thought to be responsible for the later quantitative increase in CD4 cell counts [38]. These data suggest IRIS may be due to a combination of both quantitative restoration of immunity as well as qualitative function and phenotypic expression observed soon after the initiation of ART.

The third purported pathogenic mechanism for IRIS involves host genetic susceptibility to an exuberant immune response to the infectious or noninfectious anti-

**Table 1: Infectious and noninfectious causes of IRIS in HIV-infected patients**

Infectious Etiologies	Noninfectious etiologies
Mycobacteria	Rheumatologic/Autoimmune
<i>Mycobacterium tuberculosis</i> [4, 6, 7, 10, 11, 26, 30-32, 41, 43, 45]	Rheumatoid arthritis [29] Systemic lupus erythematosus (SLE) [91]
<i>Mycobacterium avium</i> complex [4, 5, 23, 31, 94-96]	Graves disease [92], Autoimmune thyroid disease [93]
Other mycobacteria [4, 56, 57, 98, 99]	Sarcoidosis & granulomatous reactions [20, 97]
Cytomegalovirus [4, 33, 61, 63]	Tattoo ink [100]
Herpes viruses	AIDS-related lymphoma [101]
Herpes zoster virus [4, 32, 33, 71, 103, 104]	Guillain-Barre' syndrome (GBS) [102]
Herpes simplex virus [4, 32, 33]	Interstitial lymphoid pneumonitis [105]
Herpes virus-associated Kaposi's sarcoma [4, 32, 106]	
<i>Cryptococcus neoformans</i> [13, 16, 22, 28, 31, 83, 84, 86, 88]	
<i>Pneumocystis jirovecii</i> pneumonia (PCP) [8, 14, 32]	
<i>Histoplasmosis capsulatum</i> [107]	
Toxoplasmosis [33]	
Hepatitis B virus [32, 33]	
Hepatitis C virus [4, 32, 33, 108]	
Progressive multifocal leukoencephalitis [12, 33, 109]	
Parvovirus B19 [110]	
<i>Strongyloides stercoralis</i> infection [111] & other parasitic infections [112]	
Molluscum contagiosum & genital warts [32]	
Sinusitis [113]	
Folliculitis [114, 115]	

genic stimulus upon immune restoration. Although evidence is limited, carriage of specific HLA alleles suggest associations with the development of IRIS and specific pathogens [39]. Increased levels of interleukin-6 (IL-6) in IRIS patients may explain the exuberant Th1 response to mycobacterial antigens in subjects with clinical IRIS [9,40]. Such genetic predispositions may partially explain why manifestations of IRIS differ in patients with similar antigenic burden and immunological responses to ART.

### Epidemiology of IRIS

Despite numerous descriptions of the infectious and non-infectious causes of IRIS, the overall incidence of the syndrome itself remains largely unknown. Studies to date are often retrospective and focus on specific manifestations of IRIS, such as tuberculosis-associated IRIS (TB-IRIS). In a large retrospective analysis examining all forms of IRIS, 33/132 (25%) of patients exhibited one or more disease episodes after initiation of ART [4]. Other cohort analyses examining all manifestations of IRIS estimate that 17–23% of patients initiating ART will develop the syndrome [32-34]. Another large retrospective study reported 32% of patients with *M. tuberculosis*, *M. avium* complex, or *Cryptococcus neoformans* coinfection developed IRIS after initiating ART.

Risk factors identified for the development of IRIS in one cohort included male sex, a shorter interval between initiating treatment for OI and starting ART, a rapid fall in HIV-1 RNA after ART, and being ART-naïve at the time of OI diagnosis [31]. Other significant predictors have also

included younger age, a lower baseline CD4 cell percentage, a lower CD4 cell count at ART initiation, and a lower CD4 to CD8 cell ratio at baseline [4,32]. It should be noted cohorts differ substantially in study populations and the type of IRIS (i.e. TB-IRIS only) examined, making conclusions regarding risk factors for IRIS difficult. Clinical factors associated with the development of IRIS are presented in Table 2.

Case reports describing different clinical manifestations of IRIS continue to appear, expanding the clinical spectrum of the syndrome. Because the definition of IRIS is one of clinical suspicion and disease-specific criteria have yet to be developed, determining the true incidence will be difficult. Taken together, these studies suggest IRIS may affect a substantial proportion of HIV patients initiating ART. Future epidemiologic and genetic studies conducted within diverse cohorts will be important in determining the importance of host susceptibility and underlying opportunistic infections on the risk of developing IRIS.

### Disease-specific manifestations of IRIS

In order to aid clinicians in the management of IRIS, we review the epidemiology, clinical features, and treatment options for the common infectious manifestations of IRIS. Additionally, manifestations associated with significant morbidity and mortality, such as CMV-associated immune recovery vitritis (IRV) or immune recovery uveitis (IRU), are also reviewed. Treatment options and their evidence are presented. Until disease specific guidelines are developed for IRIS, therapy should be based on exist-

**Table 2: Clinical factors associated with the development of IRIS†**

Risk factor	Reference
Male sex	[31]
Younger age	[32]
Lower CD4 cell count at ART initiation	[4]
Higher HIV RNA at ART initiation	[4]
Lower CD4 cell percentage at ART initiation	[32]
Lower CD4:CD8 ratio at ART initiation	[32]
More rapid initial fall in HIV RNA on ART	[31]
Antiretroviral naïve at time of OI diagnosis	[31]
Shorter interval between OI therapy initiation and ART initiation	[31]

†Derived from cohorts where IRIS due to multiple pathogens were reported (i.e. cohorts which examined only TB-IRIS were excluded)

ing evidence and individualized according to the severity of presentation.

### ***Mycobacterium tuberculosis* IRIS**

#### *Epidemiology*

*Mycobacterium tuberculosis* (TB) is among the most frequently reported pathogen associated with IRIS. Narita *et al* performed the first prospective study to evaluate the incidence of paradoxical responses in patients on TB therapy and subsequently initiated on ART. Of 33 HIV/TB coinfecting patients undergoing dual therapy, 12 (36%) developed paradoxical symptoms [7]. The frequency of symptoms in this group were greater than those observed in HIV-infected controls receiving TB therapy alone, supporting the role of an exaggerated immune system response in the pathogenesis of the syndrome. Retrospective studies corroborate the finding that a significant proportion of HIV/TB coinfecting patients undergoing HAART have symptoms consistent with IRIS, with estimates ranging from 7–45% [10,26,30,35,41-43].

The association between a shorter delay between TB treatment initiation and ART initiation is an area of debate. While some investigators have found no difference in time from TB therapy to initiation of ART between IRIS and non-IRIS subjects [30], others have reported a significant differences between groups [31,35]. In general, IRIS occurred in subjects initiated on ART within two months of TB therapy initiation [35]. Based on these and other data, a decision analysis on ART initiation timing in TB patients found the highest rates of IRIS occurred in patients initiated on ART within two months of TB therapy initiation [44]. However, withholding or deferring ART until two to six months of TB therapy was associated with higher mortality in scenarios where IRIS-related mortality was less than 4.6%. Future reports from large, prospective observational cohorts may aid in resolving this difficult issue.

Although consisting primarily of case reports [45,46], TB-IRIS affecting the central nervous system (CNS) poses a

unique problem. As the availability of ART increases in endemic countries, the incidence of CNS TB-IRIS may increase. Thus, clinicians should be vigilant in its diagnosis.

#### *Clinical features*

The commonest clinical manifestations of TB-IRIS are fever, lymphadenopathy and worsening respiratory symptoms [47]. Pulmonary disorders, such as new pulmonary infiltrates, mediastinal lymphadenopathy, and pleural effusions are also common [7]. Extrapulmonary presentations are also possible, including disseminated tuberculosis with associated acute renal failure [6], systemic inflammatory responses (SIRS) [48], and intracranial tuberculomas [45]. Pulmonary TB-IRIS can be diagnosed by transient worsening of chest radiographs, especially if old radiographs are available for comparison. Other symptoms are nonspecific, and include persistent fever, weight loss, and worsening respiratory symptoms. Abdominal TB-IRIS can present with nonspecific abdominal pain and obstructive jaundice.

In most studies, TB-IRIS occurs within two months of ART initiation [6,7,10,11,25,35,45,48]. Among 43 cases of MTB-associated IRIS, the median onset of IRIS was 12–15 days (range 2–114 days), with only four of these cases occurring more than four weeks after the initiation of antiretroviral therapy [7,10,25,26,30]. These studies suggest the onset of mycobacterial-associated IRIS is relatively soon after initiation of ART, and clinicians should maintain a high level of vigilance during this period.

Paradoxical CNS TB reactions are well described in HIV-negative patients, and include expanding intracranial tuberculomas, tuberculous meningitis, and spinal cord lesions [49-51]. TB-associated CNS IRIS has also been reported in HIV-positive patients [45,46,52]. Compared to non-CNS TB-IRIS, symptoms tend to occur later, usually 5–10 months after ART initiation [45,50,52]. Crump *et al* [45] described an HIV-seropositive patient in who developed cervical lymphadenopathy after five weeks of

ART. Five months later, CNS symptoms associated with an expanding intracranial tuberculoma appeared after initiation of antituberculous therapy. The significant morbidity in this case illustrates the importance of maintaining a high clinical suspicion for the disease, particularly in endemic areas.

#### Treatment

Treatment for mycobacterial-associated IRIS depends on the presentation and disease severity. Most patients present with non-life threatening presentations which respond to the institution of appropriate antituberculous therapy. However a range of life threatening presentations, such as acute renal failure [6] and acute respiratory distress syndrome (ARDS) [11], are described and have significant morbidity and mortality. Morbidity and mortality might also be greater in resource-limited settings where limited management options exist. Since the pathogenesis of the syndrome is an inflammatory one, systemic corticosteroids or nonsteroidal anti-inflammatory drugs (NSAIDs) may alleviate symptoms. In studies where therapy for IRIS was mentioned, the use of corticosteroids was variable [7,24,25,31,41,43] and anecdotally effective. Therapies ranged from intravenous methylprednisolone 40 mg every 12 hours to prednisone 20–70 mg/day for 5–12 weeks. These practices reflect the lack of evidence from controlled trials for the use of anti-inflammatory agents in IRIS. A randomized, placebo controlled trial examining doses of prednisone 1.5 mg/kg/day for two weeks followed by 0.75 mg/kg/day for two weeks in mild to moderate TB-IRIS is currently underway in South Africa. Until data become available, it is reasonable to administer corticosteroids for severe cases of IRIS such as tracheal compression due to lymphadenopathy, refractory or debilitating lymphadenitis, or severe respiratory symptoms, such as stridor and ARDS. Interruption of ART is rarely necessary but could be considered in life-threatening situations.

In HIV-negative patients, adjuvant corticosteroid use in tuberculous meningitis provides evidence of improved survival and decreased neurologic sequelae over standard therapy alone [53,54]. Once other infectious etiologies, have been excluded, standard antituberculous therapy should be initiated or continued as the clinical situation dictates, and a course of corticosteroid therapy should be considered for CNS TB-IRIS. Continuation of ART is desirable, although its discontinuation may be necessary in unresponsive cases or in those presenting with advanced neurological symptoms.

#### **Atypical mycobacterial IRIS**

##### *Epidemiology*

In addition to TB, atypical mycobacteria are also frequently reported as causative pathogens in IRIS. Early

observations involving atypical presentations of *Mycobacterium avium-intracellulare* (MAC) were first noted with zidovudine therapy [55]. Reports of atypical presentations of both *Mycobacterium tuberculosis* (MTB) and MAC increased in frequency with the introduction of protease inhibitors and ART. In larger cohorts, MAC remains the most frequently reported atypical mycobacterium [4,5,24]. Other atypical mycobacteria rarely associated with IRIS are referenced in Table 1.

##### *Clinical features*

In general, MAC-associated IRIS typically presents with lymphadenitis, with or without abscess formation and suppuration [5]. Other less common presentations include respiratory failure secondary to acute respiratory distress syndrome (ARDS) [56], leprosy [57], pyomyositis with cutaneous abscesses [23], intra-abdominal disease [58], and involvement of joints, skin, soft tissues, and spine [58,59].

Several studies have characterized the time of onset of *Mycobacterium*-associated IRIS. In one study of MAC lymphadenitis, the onset of a febrile illness was the first sign of IRIS and occurred between 6 and 20 days after initiation of antiretroviral therapy [5]. In another study, the median time interval from the start of antiretroviral therapy to the development of mycobacterial lymphadenitis was 17 days (range 7–85 days) [24].

##### *Treatment*

As with TB-IRIS, evidence for treatment of IRIS due to atypical mycobacteria are scarce. Occasionally, surgical excision of profoundly enlarged nodes or debridement of necrotic areas is anecdotally reported [23,59]. However, healing is often poor leaving large, persistent sinuses. Needle aspiration is another option for enlarged, fluctuant and symptomatic nodes. Otherwise, treatment is similar to TB-IRIS (see *Mycobacterium tuberculosis* IRIS – Treatment).

#### **Cytomegalovirus infection**

##### *Epidemiology*

In the pre-ART era, CMV retinitis, a vision-threatening disease, carried a high annual incidence and was one of the most significant AIDS-associated morbidities [60]. After the introduction of HAART, Jacobson et al described five patients diagnosed with CMV retinitis 4–7 weeks after ART initiation. They speculated that an HAART-induced inflammatory response may be responsible for unmasking a subclinical infection [17]. In addition to classical CMV retinitis, ART led to new clinical manifestations of the infection, termed immune recovery vitritis (IRV) or immune recovery uveitis (IRU), in patients previously diagnosed with inactive AIDS-related CMV retinitis [61]. Distinct from the minimal intraocular inflammation of

classic CMV retinitis, these manifestations exhibit significant posterior segment ocular inflammation thought to be due to the presence of residual CMV antigens or proteins which serve as the antigenic stimulus for the syndrome [62]. Clinical manifestations include vision impairment and floaters.

In a retrospective cohort, CMV-related IRIS was common (6/33 of IRIS cases, or 18%) [4]. In prospective cohorts, symptomatic vitritis occurred in 63% (incidence rate 83 per 100 p-yr) of ART responders who carried a previous diagnosis of CMV retinitis but had inactive disease at the onset of antiretroviral therapy. The median time from ART initiation to IRV was (43 weeks)[63]. Another large prospective surveillance study [64] identified 374 patients with a history of CMV retinitis involving 539 eyes. Thirty-one of 176 ART responders (17.6%) were diagnosed with IRU. Male gender, use of ART, higher CD4 cell counts, and involvement of the posterior retinal pole as factors associated with a reduced risk of developing IRU, whereas prior use of intravitreal injections of cidofovir, large retinal lesions, and adequate immune recovery on ART were associated with increased risk.

#### *Clinical features & treatment*

The diagnosis of ocular manifestations of IRIS requires a high level of suspicion. In addition to signs of retinitis, inflammatory symptoms include vitritis, papillitis, and macular edema, resulting in symptoms of loss of visual acuity and floaters in affected eyes. Treatment of IRIS associated CMV retinitis and IRV may involve anti-CMV therapy with gancyclovir or valgancyclovir[17,65]. However, the occurrence of IRU in patients receiving anti-CMV therapy draws its use into question [64,66,67]. The use of systemic corticosteroids has been successful, and IRV may require periocular corticosteroid injections [61,68-70]. Due to its significant morbidity and varying temporal presentations, clinicians should maintain a high level of vigilance for ocular manifestations of CMV-associated IRIS.

#### **Varicella zoster virus infection**

##### *Epidemiology*

With the introduction of protease inhibitors, increasing rates of herpes zoster were noted in HIV-infected patients. Two studies comparing ART and non-ART patients reported increased incident cases of zoster and rates estimated at 6.2–9.0 cases per 100 person-years, three to five times higher than rates observed in the pre-HAART era [18,71]. While another study [72] reported no difference in overall incidence between HAART eras (3.2 cases per 100 person-years), the use of HAART was associated with increased odds of developing an incident zoster outbreak (OR = 2.19, 95% confidence interval: 1.49 to 3.20). These studies suggest that ART may play a role in increasing the

risk of zoster, which is reflected in large observational IRIS cohorts, where dermatomal varicella zoster comprises 9–40% of IRIS cases [4,32,33]. Mean onset of disease from ART initiation was 5 weeks (range 1–17 weeks) [71], and no cases occurred before 4 weeks of therapy [18]. Both studies identified significant increases in CD8 T cells as a risk factor for developing dermatomal zoster.

#### *Clinical features & treatment*

Although complications such as encephalitis, myelitis, cranial and peripheral nerve palsies, and acute retinal necrosis can occur in immunocompromised HIV patients, the vast majority of patients exhibit typical or atypical dermatomal involvement without dissemination or systemic symptoms [18,71,73].

A randomized, controlled trial demonstrated oral acyclovir to be effective for dermatomal zoster in HIV-infected patients, facilitating healing and shortening the time of zoster-associated pain [74]. Its use in cases of varicella zoster IRIS appears to be of clinical benefit [18]. The benefit of corticosteroids in combination with acyclovir in acute varicella zoster has been demonstrated in two large randomized, controlled trials. The combination of corticosteroids and acyclovir decreased healing times, improved acute pain, and quality of life, but did not affect the incidence or duration of postherpetic neuralgia [75,76]. The incidence of postherpetic neuralgia in immunocompetent individuals does not differ significantly from HIV-infected patients, but increases with increasing patient age [77]. Successful symptomatic management involving opioids, tricyclic antidepressants, gabapentin, and topical lidocaine patches individually or in combination has been shown to be beneficial [78-82] and should be attempted in HIV patients with postherpetic neuralgia as a complication of herpes zoster IRIS.

#### **Cryptococcus neoformans infection**

##### *Epidemiology*

Accurate incidence of *C. neoformans*-associated IRIS is unknown. It is infrequently reported in overall IRIS cohorts, and many cases appear as single case reports. The majority of cryptococcal IRIS cases represent reactivation of previously treated cases [13,16,21,22,83-86], suggesting either an immunological reaction to incompletely treated disease or an inflammatory reaction to residual antigens. Although reports of cryptococcal lymphadenitis and mediastinitis have been reported [87,88], most cryptococcal IRIS cases present as meningitis. Of 41 well documented cases of cryptococcal IRIS meningitis, 33 (80%) result as a reactivation of *C. neoformans* meningitis [13,16,21,22,83-86,89], illustrating the importance of maintaining a high clinical suspicion for patients at risk for cryptococcal IRIS, even in those previously treated.

### Clinical features

*C. neoformans*-induced IRIS meningitis symptoms range in onset from seven days to ten months after initiation of ART, with 20 (49%) occurring within four weeks of therapy [13,16,21,22,83-86,89]. In one study [85], patients with *C. neoformans*-related IRIS meningitis were compared to typical AIDS-related *C. neoformans* meningitis. Patients with *C. neoformans*-related IRIS meningitis exhibited no difference in clinical presentation. However, *C. neoformans*-related IRIS patients exhibited had higher baseline plasma HIV RNA levels and higher CSF cryptococcal antigen titers, opening pressures, WBC counts, and glucose levels. Additionally, IRIS patients were more likely to have ART initiated within 30 days of previously diagnosed *C. neoformans* meningitis. Most documented cases of *C. neoformans*-induced IRIS meningitis have occurred in patients with CD4 counts <100 cells/mm<sup>3</sup> [13,21,83-85,87].

### Treatment

A recent study [90] evaluated antifungal combination therapies in the treatment of *C. neoformans* meningitis in HIV patients. Although significant log reductions in colony forming units were observed with all combinations, substantial numbers of patients remained culture positive 2 weeks after therapy. It may be important to delay ART until CSF sterility can be achieved with effective antifungal combinations such as amphotericin B and flucytosine. However, the exact timing of ART and whether attaining CSF culture sterility is important in avoiding IRIS is unknown. This is illustrated by cases of reactivation cryptococcal meningitis described in four patients who had received at least four weeks of antifungal therapy prior to ART [13,22,83]. It is reasonable to administer systemic corticosteroids to alleviate unresponsive inflammatory effects, as anecdotal benefits have been observed in these patients [21,84]. Furthermore, serial lumbar punctures may be required to manage persistent CSF pressure elevations in these patients [85,86]. Although continuation of ART has been performed safely [13,84], interruption of antiviral therapy may be necessary in severe or unresponsive cases.

### Other etiologies

Other less common infectious etiologies, as well as non-infectious etiologies, are listed in Table 1. Because these other infectious and non-infectious etiologies are rare, no recommendations exist for their management.

### Conclusion

While exact estimates of incidence are not yet available, IRIS in patients initiating ART has been firmly established as a significant problem in both high and low income countries. Because of wide variation in clinical presentation and the still increasing spectrum of symptoms and etiologies reported, diagnosis remains problematic. Fur-

thermore, no test is currently available to establish an IRIS diagnosis. Standardized disease-specific clinical criteria for common infectious manifestations of the disease should be developed to: 1) identify risk factors for developing the syndrome and 2) optimize the prevention, management of opportunistic infections. Results of trials addressing the optimal timing and duration of treatment of opportunistic infections will assist in developing guidelines for the prevention and management of IRIS. Treatment of IRIS will remain a clinical challenge due to the variety of clinical presentations and the presence of multiple pathogens capable of causing the syndrome. Until a greater understanding of the syndrome is achieved in different regions of the world, clinicians need to remain vigilant when initiating ART and individualize therapy according to known treatment options for the specific infectious agent.

### Competing interests

The author(s) declare that they have no competing interests.

### Authors' contributions

All authors participated in the drafting of the manuscript. All authors read and approved the final manuscript.

### Acknowledgements

None

### References

1. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Sat-ten GA, Aschman DJ, Holmberg SD: **Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.** *N Engl J Med* 1998, **338(13)**:853-860.
2. Gea-Banacloche JC, Clifford Lane H: **Immune reconstitution in HIV infection.** *Aids* 1999, **13 Suppl A**:S25-38.
3. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A: **AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.** *Jama* 1999, **282(23)**:2220-2226.
4. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, Tay-Kearney ML: **Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy.** *HIV Med* 2000, **1(2)**:107-115.
5. Race EM, Adelson-Mitty J, Krieger GR, Barlam TF, Reimann KA, Letvin NL, Japour AJ: **Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.** *Lancet* 1998, **351(9098)**:252-255.
6. Jehle AW, Khanna N, Sigle JP, Glatz-Krieger K, Battegay M, Steiger J, Dickenmann M, Hirsch HH: **Acute renal failure on immune reconstitution in an HIV-positive patient with miliary tuberculosis.** *Clin Infect Dis* 2004, **38(4)**:e32-5.
7. Narita M, Ashkin D, Hollender ES, Pitchenik AE: **Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.** *Am J Respir Crit Care Med* 1998, **158(1)**:157-161.
8. Koval CE, Gigliotti F, Nevins D, Demeter LM: **Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection.** *Clin Infect Dis* 2002, **35(4)**:491-493.
9. Stone SF, Price P, Keane NM, Murray RJ, French MA: **Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with**

- a history of immune restoration disease after HAART. *HIV Med* 2002, **3(1)**:21-27.
10. Fishman JE, Saraf-Lavi E, Narita M, Hollender ES, Ramsinghani R, Ashkin D: **Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy.** *AJR Am J Roentgenol* 2000, **174(1)**:43-49.
  11. Goldsack NR, Allen S, Lipman MC: **Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy.** *Sex Transm Infect* 2003, **79(4)**:337-338.
  12. Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL: **Fatal immune restoration disease in human immunodeficiency virus type I-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution.** *Clin Infect Dis* 2002, **35(10)**:1250-1257.
  13. Jenny-Avital ER, Abadi M: **Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy.** *Clin Infect Dis* 2002, **35(12)**:e128-33.
  14. Crothers K, Huang L: **Recurrence of *Pneumocystis carinii* pneumonia in an HIV-infected patient: apparent selective immune reconstitution after initiation of antiretroviral therapy.** *HIV Med* 2003, **4(4)**:346-349.
  15. Wislez M, Bergot E, Antoine M, Parrot A, Carette MF, Mayaud C, Cadranet J: **Acute respiratory failure following HAART introduction in patients treated for *Pneumocystis carinii* pneumonia.** *Am J Respir Crit Care Med* 2001, **164(5)**:847-851.
  16. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G: **Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution.** *Clin Infect Dis* 2006, **43(8)**:1069-1073.
  17. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, Owens S, Pollard R: **Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.** *Lancet* 1997, **349(9063)**:1443-1445.
  18. Martinez E, Gatell J, Moran Y, Aznar E, Buiria E, Guelar A, Mallolas J, Soriano E: **High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors.** *Clin Infect Dis* 1998, **27(6)**:1510-1513.
  19. Mastroianni CM, Trinchieri V, Santopadre P, Lichtner M, Forcina G, D'Agostino C, Corpolongo A, Vullo V: **Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy.** *Aids* 1998, **12(14)**:1939-1940.
  20. Naccache JM, Antoine M, Wislez M, Fleury-Feith J, Oksenhendler E, Mayaud C, Cadranet J: **Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy.** *Am J Respir Crit Care Med* 1999, **159(6)**:2009-2013.
  21. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC Jr., Visnegarwala F, Trautner BW: **Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.** *Medicine (Baltimore)* 2002, **81(3)**:213-227.
  22. Woods ML 2nd, MacGinley R, Eisen DP, Allworth AM: **HIV combination therapy: partial immune reconstitution unmasking latent cryptococcal infection.** *Aids* 1998, **12(12)**:1491-1494.
  23. Lawn SD, Bicanic TA, Macallan DC: **Pyomyositis and cutaneous abscesses due to *Mycobacterium avium*: an immune reconstitution manifestation in a patient with AIDS.** *Clin Infect Dis* 2004, **38(3)**:461-463.
  24. Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J: **Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy.** *J Acquir Immune Defic Syndr Hum Retrovirol* 1999, **20(2)**:122-128.
  25. Orlovic D, Smego RA Jr.: **Paradoxical tuberculous reactions in HIV-infected patients.** *Int J Tuberc Lung Dis* 2001, **5(4)**:370-375.
  26. Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR: **Paradoxical worsening of tuberculosis in HIV-infected persons.** *Chest* 2001, **120(1)**:193-197.
  27. Chien JW, Johnson JL: **Paradoxical reactions in HIV and pulmonary TB.** *Chest* 1998, **114(3)**:933-936.
  28. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F: **Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France.** *Aids* 2005, **19(10)**:1043-1049.
  29. Bell C, Nelson M, Kaye S: **A case of immune reconstitution rheumatoid arthritis.** *Int J STD AIDS* 2002, **13(8)**:580-581.
  30. Breton G, Duval X, Estellat C, Paoletti X, Bonnet D, Mvondo D, Longuet P, Lepout C, Vilde JL: **Determinants of immune reconstitution inflammatory syndrome in HIV type I-infected patients with tuberculosis after initiation of antiretroviral therapy.** *Clin Infect Dis* 2004, **39(11)**:1709-1712.
  31. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr., Hamill RJ: **Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.** *Aids* 2005, **19(4)**:399-406.
  32. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ: **Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type I-infected cohort.** *Clin Infect Dis* 2006, **42(3)**:418-427.
  33. Jevtic D, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O: **The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy.** *HIV Med* 2005, **6(2)**:140-143.
  34. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V: **Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children.** *Pediatr Infect Dis J* 2006, **25(1)**:53-58.
  35. Navas E, Martin-Davila P, Moreno L, Pintado V, Casado JL, Fortun J, Perez-Elias MJ, Gomez-Mampaso E, Moreno S: **Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy.** *Arch Intern Med* 2002, **162(1)**:97-99.
  36. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J: **Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.** *Science* 1997, **277(5322)**:112-116.
  37. Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM: **Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.** *J Clin Invest* 1999, **103(10)**:1391-1398.
  38. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F, Schellekens PT: **Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.** *Nat Med* 1998, **4(2)**:208-214.
  39. Price P, Mathiot N, Krueger R, Stone S, Keane NM, French MA: **Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy.** *J Clin Virol* 2001, **22(3)**:279-287.
  40. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, Vicaut E, Lagrange PH, Sereni D, Autran B: **Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients.** *Aids* 2006, **20(2)**:F1-7.
  41. Kumarasamy N, Chaguturu S, Mayer KH, Solomon S, Yephthomi HT, Balakrishnan P, Flanigan TP: **Incidence of Immune Reconstitution Syndrome in HIV/Tuberculosis-Coinfected Patients After Initiation of Generic Antiretroviral Therapy in India.** *J Acquir Immune Defic Syndr* 2004, **37(5)**:1574-1576.
  42. Martinez V, Tl, Martinez E, Blanch JJ: **Paradoxical response to antituberculous therapy in immunocompetent patients and HIV co-infected patients.** *Program and abstracts of the 44th Annual ICAAC Meeting, Washington, DC, October 30 - November 2 2004.*
  43. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG: **Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis.** *Antivir Ther* 2005, **10(3)**:417-422.
  44. Schiffer JT, Sterling TR: **Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis.** *J Acquir Immune Defic Syndr* 2007, **44(2)**:229-234.
  45. Crump JA, Tyrer MJ, Lloyd-Owen SJ, Han LY, Lipman MC, Johnson MA: **Military tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy.** *Clin Infect Dis* 1998, **26(4)**:1008-1009.
  46. Vidal JE, Cimerman S, Schiavon Nogueira R, Bonasser Filho F, Sztajn-bok J, da Silva PR, Lins DL, Coelho JF: **Paradoxical reaction during treatment of tuberculous brain abscess in a patient with AIDS.** *Rev Inst Med Trop Sao Paulo* 2003, **45(3)**:177-178.

47. Lawn SD, Bekker LG, Miller RF: **Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.** *Lancet Infect Dis* 2005, **5(6)**:361-373.
48. Furrer H, Malinverni R: **Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis.** *Am J Med* 1999, **106(3)**:371-372.
49. Teoh R, Humphries MJ, O'Mahony G: **Symptomatic intracranial tuberculoma developing during treatment of tuberculosis: a report of 10 patients and review of the literature.** *Q J Med* 1987, **63(241)**:449-460.
50. Cheng VC, Ho PL, Lee RA, Chan KS, Chan KK, Woo PC, Lau SK, Yuen KY: **Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients.** *Eur J Clin Microbiol Infect Dis* 2002, **21(11)**:803-809.
51. Hejazi N, Hassler W: **Multiple intracranial tuberculomas with atypical response to tuberculostatic chemotherapy: literature review and a case report.** *Acta Neurochir (Wien)* 1997, **139(3)**:194-202.
52. Ramdas K, Minamoto GY: **Paradoxical presentation of intracranial tuberculomas after chemotherapy in a patient with AIDS.** *Clin Infect Dis* 1994, **19(4)**:793-794.
53. Dooley DP, Carpenter JL, Rademacher S: **Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature.** *Clin Infect Dis* 1997, **25(4)**:872-887.
54. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Tran TH, Farrar JJ: **Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.** *N Engl J Med* 2004, **351(17)**:1741-1751.
55. French MA, Mallal SA, Dawkins RL: **Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients.** *Aids* 1992, **6(11)**:1293-1297.
56. Lawn SD: **Acute respiratory failure due to Mycobacterium kansasii infection: immune reconstitution disease in a patient with AIDS.** *J Infect* 2005, **51(4)**:339-340.
57. Lawn SD, Wood C, Lockwood DN: **Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person.** *Clin Infect Dis* 2003, **36(1)**:e5-6.
58. Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, O'Shaughnessy M, Montaner J: **Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.** *Clin Infect Dis* 2005, **41(10)**:1483-1497.
59. Aberg JA, Chin-Hong PV, McCutchan A, Koletar SL, Currier JS: **Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy.** *Clin Infect Dis* 2002, **35(1)**:E8-E13.
60. Jacobson MA, Mills J: **Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.** *Ann Intern Med* 1988, **108(4)**:585-594.
61. Karavellas MP, Lowder CY, Macdonald C, Avila CP Jr., Freeman WR: **Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome.** *Arch Ophthalmol* 1998, **116(2)**:169-175.
62. Schrier RD, Song MK, Smith IL, Karavellas MP, Bartsch DU, Torriani FJ, Garcia CR, Freeman WR: **Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis.** *Retina* 2006, **26(2)**:165-169.
63. Karavellas MP, Plummer DJ, Macdonald JC, Torriani FJ, Shufelt CL, Azen SP, Freeman WR: **Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy.** *J Infect Dis* 1999, **179(3)**:697-700.
64. Kempen JH, Min YI, Freeman WR, Holland GN, Friedberg DN, Dieterich DT, Jabs DA: **Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis.** *Ophthalmology* 2006, **113(4)**:684-694.
65. Kosobucki BR, Goldberg DE, Bessho K, Koh HJ, Rodanant N, Labree L, Cheng L, Schrier RD, Azen SP, Freeman WR: **Valganciclovir therapy for immune recovery uveitis complicated by macular edema.** *Am J Ophthalmol* 2004, **137(4)**:636-638.
66. Song MK, Azen SP, Buley A, Torriani F, Cheng L, Chaidhawangul S, Ozerdem U, Scholz B, Freeman WR: **Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis.** *Am J Ophthalmol* 2003, **136(4)**:696-702.
67. Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ: **The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy.** *HIV Clin Trials* 2005, **6(3)**:136-146.
68. Arevalo JF, Mendoza AJ, Ferretti Y: **Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela.** *Retina* 2003, **23(4)**:495-502.
69. Henderson HW, Mitchell SM: **Treatment of immune recovery vitritis with local steroids.** *Br J Ophthalmol* 1999, **83(5)**:540-545.
70. Karavellas MP, Azen SP, MacDonald JC, Shufelt CL, Lowder CY, Plummer DJ, Glasgow B, Torriani FJ, Freeman WR: **Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes.** *Retina* 2001, **21(1)**:1-9.
71. Domingo P, Torres OH, Ris J, Vazquez G: **Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection.** *Am J Med* 2001, **110(8)**:605-609.
72. Gebo KA, Kalyani R, Moore RD, Polydefkis MJ: **The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era.** *J Acquir Immune Defic Syndr* 2005, **40(2)**:169-174.
73. Glesby MJ, Moore RD, Chaisson RE: **Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus.** *Clin Infect Dis* 1995, **21(2)**:370-375.
74. Gnann JW Jr., Crumpacker CS, Lalezari JP, Smith JA, Tyring SK, Baum KF, Borucki MJ, Joseph WP, Mertz GJ, Steigbigel RT, Cloud GA, Soong SJ, Sherrill LC, DeHertogh DA, Whitley RJ: **Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group.** *Antimicrob Agents Chemother* 1998, **42(5)**:1139-1145.
75. Whitley RJ, Weiss H, Gnann JW Jr., Tyring S, Mertz GJ, Pappas PG, Schleupner CJ, Hayden F, Wolf J, Soong SJ: **Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.** *Ann Intern Med* 1996, **125(5)**:376-383.
76. Wood MJ, Johnson RW, Kendrick MW, Taylor J, Mandal BK, Crooks J: **A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster.** *N Engl J Med* 1994, **330(13)**:896-900.
77. Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R: **Risk factors for postherpetic neuralgia.** *Arch Intern Med* 1997, **157(11)**:1217-1224.
78. Galer BS, Rowbotham MC, Perander J, Friedman E: **Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study.** *Pain* 1999, **80(3)**:533-538.
79. Watson CP, Babul N: **Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.** *Neurology* 1998, **50(6)**:1837-1841.
80. Watson CP, Vernich L, Chipman M, Reed K: **Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial.** *Neurology* 1998, **51(4)**:1166-1171.
81. Kanazi GE, Johnson RW, Dworkin RH: **Treatment of postherpetic neuralgia: an update.** *Drugs* 2000, **59(5)**:1113-1126.
82. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L: **Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.** *Jama* 1998, **280(21)**:1837-1842.
83. Boelaert JR, Goddeeris KH, Vanopdenbosch LJ, Casselman JW: **Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy.** *Aids* 2004, **18(8)**:1223-1224.

84. King MD, Perlino CA, Cinnamon J, Jernigan JA: **Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy.** *Int J STD AIDS* 2002, **13(10)**:724-726.
85. Shelburne SA 3rd, Darcourt J, White AC Jr., Greenberg SB, Hamill RJ, Atmar RL, Visnegarwala F: **The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy.** *Clin Infect Dis* 2005, **40(7)**:1049-1052.
86. York J, Bodi I, Reeves I, Riordan-Eva P, Easterbrook PJ: **Raised intracranial pressure complicating cryptococcal meningitis: immune reconstitution inflammatory syndrome or recurrent cryptococcal disease?** *J Infect* 2005, **51(2)**:165-171.
87. Blanche P, Gombert B, Ginsburg C, Passeron A, Stubei I, Rigolet A, Salmon D, Sicard D: **HIV combination therapy: immune reconstitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy.** *Scand J Infect Dis* 1998, **30(6)**:615-616.
88. Trevenzoli M, Cattelan AM, Rea F, Sasset L, Semisa M, Lanzafame M, Meneghetti F, Cadrobbi P: **Mediastinitis due to cryptococcal infection: a new clinical entity in the HAART era.** *J Infect* 2002, **45(3)**:173-179.
89. Cinti SK, Armstrong WS, Kauffman CA: **Case report. Recurrence of increased intracranial pressure with antiretroviral therapy in an AIDS patient with cryptococcal meningitis.** *Mycoses* 2001, **44(11-12)**:497-501.
90. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, Harrison TS: **Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.** *Lancet* 2004, **363(9423)**:1764-1767.
91. Behrens G, Knuth C, Schedel I, Mendila M, Schmidt RE: **Highly active antiretroviral therapy.** *Lancet* 1998, **351(9108)**:1057-8; author reply 1058-9.
92. Sereti I, Sarlis NJ, Arioglu E, Turner ML, Mican JM: **Alopecia universalis and Graves' disease in the setting of immune restoration after highly active antiretroviral therapy.** *Aids* 2001, **15(1)**:138-140.
93. Calabrese LH, Kirchner E, Shrestha R: **Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease.** *Semin Arthritis Rheum* 2005, **35(3)**:166-174.
94. del Giudice P, Durant J, Couillon E, Mondain V, Bernard E, Roger PM, Dellamonica P: **Mycobacterial cutaneous manifestations: a new sign of immune restoration syndrome in patients with acquired immunodeficiency syndrome.** *Arch Dermatol* 1999, **135(9)**:1129-1130.
95. Desimone JA Jr., Babinchak TJ, Kaulback KR, Pomerantz RJ: **Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals.** *AIDS Patient Care STDS* 2003, **17(12)**:617-622.
96. Salama C, Policar M, Venkataraman M: **Isolated pulmonary Mycobacterium avium complex infection in patients with human immunodeficiency virus infection: case reports and literature review.** *Clin Infect Dis* 2003, **37(3)**:e35-40.
97. Mirmirani P, Maurer TA, Herndier B, McGrath M, Weinstein MD, Berger TG: **Sarcoidosis in a patient with AIDS: a manifestation of immune restoration syndrome.** *J Am Acad Dermatol* 1999, **41(2 Pt 2)**:285-286.
98. Lawn SD, Checkley A, Wansbrough-Jones MH: **Acute bilateral parotitis caused by Mycobacterium scrofulaceum: immune reconstitution disease in a patient with AIDS.** *Sex Transm Infect* 2005, **81(6)**:517-518.
99. Manfredi R, Nanetti A, Tadolini M, Calza L, Morelli S, Ferri M, Marinacci G: **Role of Mycobacterium xenopi disease in patients with HIV infection at the time of highly active antiretroviral therapy (HAART). Comparison with the pre-Haart period.** *Tuberculosis (Edinb)* 2003, **83(5)**:319-328.
100. Silvestre JF, Albares MP, Ramon R, Botella R: **Cutaneous intolerance to tattoos in a patient with human immunodeficiency virus: a manifestation of the immune restoration syndrome.** *Arch Dermatol* 2001, **137(5)**:669-670.
101. Powles T, Thirlwell C, Nelson M, Bower M: **Immune reconstitution inflammatory syndrome mimicking relapse of AIDS related lymphoma in patients with HIV 1 infection.** *Leuk Lymphoma* 2003, **44(8)**:1417-1419.
102. Piliero PJ, Fish DG, Preston S, Cunningham D, Kinchelov T, Salgo M, Qian J, Drusano GL: **Guillain-Barre syndrome associated with immune reconstitution.** *Clin Infect Dis* 2003, **36(9)**:e111-4.
103. Clark BM, Krueger RG, Price P, French MA: **Compartmentalization of the immune response in varicella zoster virus immune restoration disease causing transverse myelitis.** *Aids* 2004, **18(8)**:1218-1221.
104. Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, Brown CL, Sleasman JW, Emmanuel PJ: **Varicella zoster as a manifestation of immune restoration disease in HIV-infected children.** *J Allergy Clin Immunol* 2004, **113(4)**:742-746.
105. Ingiliz P, Appenrodt B, Gruenhage F, Vogel M, Tschampa H, Tasci S, Rockstroh JK: **Lymphoid pneumonitis as an immune reconstitution inflammatory syndrome in a patient with CD4 cell recovery after HAART initiation.** *HIV Med* 2006, **7(6)**:411-414.
106. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, Dhillion T, Holmes P, Gazzard BG, Stebbing J: **Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma.** *J Clin Oncol* 2005, **23(22)**:5224-5228.
107. Breton G, Adle-Biassette H, Therby A, Ramanoelina J, Choudat L, Bisuel F, Huerre M, Dromer F, Dupont B, Lortholary O: **Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis.** *Aids* 2006, **20(1)**:119-121.
108. John M, Flexman J, French MA: **Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?** *Aids* 1998, **12(17)**:2289-2293.
109. Collazos J, Mayo J, Martinez E, Blanco MS: **Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients.** *Aids* 1999, **13(11)**:1426-1428.
110. Intalapaporn P, Poovorawan Y, Suankratay C: **Immune reconstitution syndrome associated with parvovirus B19-induced pure red cell aplasia during highly active antiretroviral therapy.** *J Infect* 2005.
111. Taylor CL, Subbarao V, Gayed S, Ustianowski AP: **Immune reconstitution syndrome to Strongyloides stercoralis infection.** *Aids* 2007, **21(5)**:649-650.
112. Lawn SD, Wilkinson RJ: **Immune reconstitution disease associated with parasitic infections following antiretroviral treatment.** *Parasite Immunol* 2006, **28(11)**:625-633.
113. Chan-Tack KM, Chengappa KS, Wolf JS, Kao GF, Reisler RB: **Immune reconstitution inflammatory syndrome presenting as sinusitis with inflammatory pseudotumor in an HIV-infected patient: a case report and review of the literature.** *AIDS Patient Care STDS* 2006, **20(12)**:823-828.
114. Delfos NM, Collen AF, Kroon FP: **Demodex folliculitis: a skin manifestation of immune reconstitution disease.** *Aids* 2004, **18(4)**:701-702.
115. Moyle M, Woolley JJ, Thevarajan I, Korman TM: **Eosinophilic folliculitis: an example of 'immune reconstitution folliculitis'?** *Aids* 2004, **18(17)**:2350-2352.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
http://www.biomedcentral.com/info/publishing\_adv.asp

